Immunosuppressant

Product Details:

• Triamcinolone are used to treat a number of different medical conditions, such as allergic disorders, eczema, Lichen sclerosus, psoriasis, ulcerative colitis, arthritis, ulcerative colitis, lupus, sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammation, Urushiol-induced contact dermatitis, aphthous ulcers, visualization during vitrectomy and the prevention of asthma attacks.

• Adrenal insufficiency. Triamcinolone Adults 4 to 12 mg P.O. daily, in single or divided doses.
• Children 117 mcg/kg or 3.3 mg/m2 P.O. daily, in single or divided doses.
• Severe inflammation or immunosuppression. Triamcinolone Adults 8 to 16 mg P.O. daily, in single or divided doses.
• Children 416 mcg to 1.7 mg/kg or 12.5 to 50 mg/m2 P.O. daily, in single or divided doses.
• Triamcinolone acetonide Adults Initially, 60 mg I.M. Additional doses of 20 to 100 mg may be given, p.r.n., at 6-week intervals. Or, 2.5 to 15 mg intra-articularly, or up to 1 mg intralesionally, p.r.n.
• Children ages 6 to 12 0.03 to 0.2 mg/kg I.M. at 1- to 7-day intervals.
• Triamcinolone diacetate Adults 40 mg I.M. once weekly. Or, 2 to 40 mg intra-articularly, intrasynovially, or intralesionally q 1 to 8 weeks. Or, 4 to 48 mg P.O., divided into four doses.
• Children 0.117 to 1.66 mg/kg/day P.O., divided into four doses.
• Triamcinolone hexacetonide Adults 2 to 20 mg intra-articularly q 3 to 4 weeks, p.r.n. Or, up to 0.5 mg intralesionally per square inch of skin.
• Systemic lupus erythematosus. triamcinolone. Adults 20 to 32 mg P.O. daily.
• Acute rheumatic carditis. triamcinolone. Adults 20 to 60 mg P.O. daily.
• Tuberculous meningitis. triamcinolone. Adults 32 to 48 mg P.O. daily.
• Edematous states. triamcinolone. Adults 16 to 48 mg P.O. daily.
• Collagen diseases. triamcinolone. Adults 30 to 48 mg P.O. daily.
• Dermatologic disorders. triamcinolone. Adults 8 to 16 mg P.O. daily.
• Allergic states. triamcinolone. Adults 8 to 12 mg P.O. daily.
• Ophthalmic diseases. triamcinolone. Adults 12 to 40 mg P.O. daily.
• Respiratory diseases. triamcinolone. Adults 16 to 48 mg P.O. daily.
• Hematologic diseases. triamcinolone. Adults 16 to 60 mg P.O. daily.
• Neoplastic diseases. triamcinolone. Adults 16 to 100 mg P.O. daily.

Product Details:

• Suppression of allergic and inflammatory disorders
• Symptomatic control for hay fever
• Inflammatory joint diseases
• Inflammatory skin conditions

• Adult As acetonide 20-80 mg via deep IM into gluteal muscles. As diacetate 40 mg inj.
• Child As acetonide deep IM into gluteal muscle initial 0.11 to 1.6 mg/kg/day in 3-4 divided doses. Do not use in premature infants and infants of low birth weight as it contains benzyl alcohol.

• Adult As acetonide 40-100 mg via deep IM into gluteal muscles. As diacetate 40 mg wkly.
• Child As acetonide deep IM into gluteal muscle initial 0.11 to 1.6 mg/kg/day in 3-4 divided doses. Do not use in premature infants and infants of low birth weight as it contains benzyl alcohol.

• Adult As acetonide Smaller joints 2.5-5 mg (up to 10 mg), larger joints 5-15 mg (up to 40 mg). Max 20-80 mg/treatment. As hexacetonide Initial 2-20 mg/day.

• Adult As acetonide 1-3 mg/site. Max 30 mg in total if several sites of inj used. As diacetate 5 mg in divided doses for small lesions or up to 48 mg in divided doses for large lesions. Max 12.5 mg/inj site. Max 25 mg/lesion. As hexacetonide max 500 mcg per square inch or 80 mcg/cm2 of affected skin.

Product Details:

• Prophylaxis of acute renal graft rejection
• Prophylaxis of cardiac graft rejection

• Adult As mycophenolate mofetil 1 g bid starting within 72 hr of transplantation. Max 2 g/day. As mycophenolic acid 720 mg bid.
• Child As mycophenolate mofetil 2-18 yr 600 mg/m2 bid. Max 1 g bid. BSA 1.25-1.5 m2 750 mg bid; >1.5 m2 1 g bid. As mycophenolic acid 5-16 yr 400 mg/m2 bid (max 720 mg bid). BSA 1.19-1.58 m2 540 mg bid (max 1,080 mg);
• ??>1.58 m2 720 mg bid (max 1,440 mg).
• Elderly As mycophenolic acid Max 720 mg bid.
• Renal impairment Severe chronic renal impairment (GFR <25 ml/min/1.73 m2) Avoid >1 g bid of mycophenolate mofetil.

• Adult As mycophenolate mofetil 1.5 g bid starting within 5 days after transplantation.

Product Details:

• Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted kidney. It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new kidney as if it were your own.

• Adults 720 mg twice daily.
• Pediatrics Based on a pharmacokinetic study conducted in stable renal pediatric transplant patients, the recommended dose in stable pediatric patients is 400 mg/m2 body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily).

Product Details:

• Tacrolimus Capsule is used for Heart Transplantation, Liver Transplantation, Kidney Or Other Organs Transplantation, Skin Diseases and other conditions. Tacrolimus Capsule contains Tacrolimus as an active ingredient. Tacrolimus Capsule works by preventing the body's immune system from attacking the newly transplanted organ.
• Tacrolimus Capsule is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms Heart Transplantation,Liver Transplantation,Kidney Or Other Organs Transplantation,Skin Diseases.

• Adult Initially, 200-300 mcg/kg daily, given in 2 divided doses (immediate-release) or once daily (extended-release). Start w/in 24 hr after transplant.
• Child As immediate-release tab/cap Initially, 300 mcg/kg daily in 2 divided doses. Start w/in 24 hr after transplant. Adolescents 200mcg/kg daily.

• Adult Initially, 100-200 mcg/kg daily, given in 2 divided doses (immediate-release) or once daily (extended-release). Start w/in 12 hr after transplant.
• Child As immediate-release tab/cap Initially, 300 mcg/kg daily in 2 divided doses. Start approx 12 hr after transplant.

• Adult Initially, 75 mcg/kg daily, after antibody induction w/in 5 days after transplant and when patient is stable, given in 2 divided doses (immediate-release) or once daily (extended-release).
• Child As immediate-release tab/cap Initially, 100-300 mcg/kg daily in 2 divided doses after antibody induction. Start w/in 5 days after transplant and when patient is stable.

• Adult In patient resistant to conventional immunosuppressive agents Initially, 200-300 mcg/kg daily, given in 2 divided doses (immediate-release) or once daily (extended-release).
• Child In patient resistant to conventional immunosuppressive agents As immediate-release tab/cap Initially, 300 mcg/kg daily in 2 divided doses.

• Adult In patient resistant to conventional immunosuppressive agents Initially, 100-200 mcg/kg daily, given in 2 divided doses (immediate-release) or once daily (extended-release).
• Child In patient resistant to conventional immunosuppressive agents As immediate-release tab/cap Initially, 300 mcg/kg daily in 2 divided doses.

• Adult In patient resistant to conventional immunosuppressive agents Initially, 150 mcg/kg daily, given in 2 divided doses (immediate-release) or once daily (extended-release).
• Child In patient resistant to conventional immunosuppressive agents As immediate-release tab/cap Initially, 200-300 mcg/kg daily in 2 divided doses.

• Adult In patient resistant to conventional immunosuppressive agents Initially, 100-150 mcg/kg daily, given in 2 divided doses (immediate-release) or once daily (extended-release).

• Adult In patient resistant to conventional immunosuppressive agents Initially, 200 mcg/kg daily, given in 2 divided doses (immediate-release) or once daily (extended-release).

• Adult In patient resistant to conventional immunosuppressive agents Initially, 300 mcg/kg daily, given in 2 divided doses (immediate-release) or once daily (extended-release).

Product Details:

• Allergic and inflammatory disorders
• Poorly controlled, moderate to severe asthma
• Nephrotic syndrome
• Rheumatoid arthritis
• Multiple sclerosis
• Infantile spasms
• Idiopathic thrombocytopenic purpura

• Adult 5-60 mg daily in 2-4 divided doses. Maintenance 2.5-15 mg daily. Withdrawal should be gradual after long-term therapy.
• Child 1 mth-18 yr Autoimmune inflammatory disorders Initially, 1-2 mg/kg once daily; may reduce dose gradually after a few days if needed. Max 60 mg daily.
• Autoimmune hepatitis Initially, 2 mg/kg once daily, then reduce to minimum effective dose. Max 40 mg daily.

• Adult Patients with at least 2 exacerbations/yr requiring oral corticosteroids 40-60 mg daily in 1-2 divided doses; usually given as a short course treatment over 3-10 days until symptom resolution and patient achieves a peak expiratory flow (PEF) of at least 80% of his or her personal best. May be used with maintenance dosages of inhaled corticosteroid and a long-acting inhaled ??2-agonist bronchodilator.
• Child Patients with >3 exacerbations/yr in children ???4 yr or at least 2 exacerbations/yr in children 5-11 yr 1-2 mg/kg daily for 3-5 days may be used with existing asthma treatment; dose may be given in 1-2 divided doses. Max 60 mg daily.

• Child 1 mth-18 yr Initially, 60 mg/m2 (max 80 mg) once daily for 4 wk until urine is protein-free followed by 40 mg/m2 every other day for 4 wk, then withdraw dose gradually. Prevention of relapse 0.5-1 mg/kg once daily every other day for 3-6 mth.

• Adult Initially, 5-7.5 mg daily, adjusted as necessary.
• Elderly 5 mg daily.

• Adult 200 mg daily for 1 wk followed by 80 mg every other day for 1 mth.

• Child 1 mth-2 yr Initially, 10 mg 4 times daily for 14 days; increase to 20 mg 3 times daily for 7 days if seizures are not controlled after 7 days; reduce dose slowly over 15 days until therapy is stopped. For patients taking 40 mg daily, reduce dose in steps of 10 mg every 5 days, then stop; in patients taking 60 mg daily, reduce dose to 40 mg daily for 5 days, then 20 mg daily for 5 days, then 10 mg daily for 5 days, then stop.

• Child 1-10 yr 1-2 mg/kg daily (max 14 days) or 4 mg/kg daily (max 4 days).

Product Details:

• Prophylaxis of graft rejection in bone marrow transplantation
• Immunosuppression in organ transplantation

• Prophylaxis of graft rejection in bone marrow transplantation
• Adult Intially, 3-5 mg/kg/day starting on the day before transplantation and continue for up to 2 wk or until oral therapy can be initiated at a maintenance of 12.5 mg/kg/day. Continue maintenance dose for at least 3-6 mth.

• Adult Initially 5-6 mg/kg/day as a single dose, infuse dose over 2-6 hr. Switch to an oral dosage form as soon as possible.????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????

Product Details:

• Prophylaxis of rejection in organ and tissue transplant
• Auto-immune diseases
• Rheumatoid arthritis
• Renal homotransplantation

• Prophylaxis of rejection in organ and tissue transplant
• Adult 1-5 mg/kg daily. Adjust according to clinical response and haematological tolerance.
• Child Same as adult dose.

• Adult 1-3 mg/kg daily. Discontinue treatment if there is no improvement after 3-6 mth.
• Child Same as adult dose.

• Adult Initially, 1 mg/kg daily in 1-2 divided doses for 6-8 wk, may increase by 0.5 mg/kg 4 wkly until response or up to 2.5 mg/kg daily. Maintenance Reduce dose by 0.5 mg/kg 4 wkly to achieve lowest effective dose.
• Child Same as adult dose.

• Adult Initially, 3-5 mg/kg daily as a single dose starting on the day of transplantation, may be given 1-3 days prior to transplantation in some cases. Maintenance 1-3 mg/kg daily.
• Child Same as adult dose.